NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar...

Related Keywords

Massachusetts ,United States ,France ,French ,Jonathan Javitt ,Matthew Duffy ,Andrew Nierenberg ,Jeremy Feffer ,Exchange Commission ,Nasdaq ,Lotus Pharmaceuticals Inc ,Lotus ,Therapeutics Inc ,Alvogen Inc ,Nrx Pharmaceuticals ,Us National Institutes Of Health ,Nrx Pharmaceuticals Inc ,Specialty Pharmaceutical Company ,Securities Exchange ,Treatment Resistant Bipolar Depression Study ,Breakthrough Therapy Designation ,Fast Track Designation ,Biomarker Letter ,Special Protocol Agreement ,Suicidal Treatment Resistant Bipolar ,Severe Bipolar Depression ,Acute Suicidal Ideation ,Special Protocol ,New Drug ,Chief Scientist ,New Drug Application ,Principal Investigator ,Massachusetts General ,Montgomery Asberg Depression Rating Scale ,Clinical Global Impression Suicidality Scale ,Breakthrough Therapy ,Hope Therapeutics ,Pharmaceutical Company ,Securities Exchange Act ,Securities Act ,Annual Report ,News Publishing ,Markets ,